The melanoma abstracts discussed in this highlights report will focus on three main themes. First, three abstracts will be discussed addressing adjuvant therapy in patients with high-risk melanoma. Secondly, long-term data were presented of a phase III study assessing pembrolizumab in ipilimumab-naïve advanced melanoma patients, followed by the 5-year overall survival (OS) data of a study with dabrafenib and trametinib in BRAFV600 mutant metastatic melanoma. The third and last part of this summary will discuss the data of three clinical studies looking into the treatment of melanoma patients with brain metastasis. For a more complete overview of melanoma data presented at ASCO 2017 we would like to refer to the official congress website (